
Use of cell-free DNA (cfDNA) testing at 10 weeks’ gestation to routinely screen for trisomies 21, 18, and 13 is achievable and it yields lower false-positive rates compared with combined testing. The downside, however, is that abnormal results must be validated by chorionic villus sampling (CVS), according to new research in the journal Ultrasound in Obstetrics & Gynecology.
